WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA clearance of the SpaceOAR® System, the first product in the United States cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many advancements in PCa radiotherapy, the close prostate-rectum proximity makes it challenging to deliver adequate radiation to the prostate without injuring the rectum (defined as the Organ At Risk - OAR). The SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for PCa, creating space to protect the anterior rectum from radiation exposure.
“For years, hydrogel products have been used safely to protect the most sensitive parts of the body as sealants and adhesion barriers, and now prostate cancer patients will also be able to benefit,” said John Pedersen, chief executive officer, Augmenix. “FDA clearance of the SpaceOAR System represents a significant development in advancing the safety, precision and flexibility with which prostate cancer radiotherapy can be delivered. Our focus at Augmenix will now turn toward working judiciously with providers to make the SpaceOAR System available to patients in the coming months.”
Placed through a small needle, the hydrogel is administered as a liquid, but quickly solidifies into a soft gel that expands the space between the prostate and rectum. The hydrogel spacer maintains this space until radiotherapy is complete. The spacer then liquefies and is absorbed and cleared from the body in the patient’s urine.
“SpaceOAR hydrogel is a valuable new tool for urologists and radiation oncologists and should be instrumental in the adoption of advanced prostate cancer radiotherapy protocols,” said John Sylvester, MD, of Lakewood Ranch Oncology in Bradenton, Florida and a principal investigator in the SpaceOAR clinical trial. “Shielding the rectum from radiation may enable the utilization of dose escalation (more prostate radiation for improved cancer kill rates) and hypofractionation (fewer radiation treatment sessions), both of which should have substantial patient benefits and help reduce healthcare costs.”
According to the American Cancer Society and the National Cancer Institute, prostate cancer is second only to skin cancer as the most frequently diagnosed cancer in men with an estimated 220,800 new cases and 27,540 deaths in the U.S. in 2015 alone. Worldwide PCa is expected to grow to 1.7 million new cases and 499,000 deaths by 2030 due to the aging population. Following PCa diagnosis, treatment options are usually limited to surgery, radiotherapy or active surveillance, where no immediate therapeutic treatment occurs.
FDA clearance was granted following completion of the SpaceOAR System prospective, multicenter, randomized clinical trial. SpaceOAR patients experienced a significant reduction in rectal radiation dose and severity of late rectal toxicity when compared to control patients who did not receive SpaceOAR hydrogel. The full pivotal clinical trial results have been submitted for publication in a peer-reviewed journal and are expected to be published later this year.
The SpaceOAR System is also CE marked and TGA approved. Augmenix also markets TraceIT® hydrogel, an absorbable tissue marker with CT, MRI and ultrasound visibility. TraceIT hydrogel is FDA cleared and CE marked, and is finding utility as a marker to improve radiation targeting of bladder tumors.
About Augmenix, Inc.
Augmenix, Inc. is a privately held
company based in Waltham, MA focused on the development and
commercialization of radiation oncology products using its proprietary
hydrogel technology. The company was founded by Incept LLC in 2008 and
is funded by several leading venture capital groups. More information
about Augmenix can be found at http://www.Augmenix.com.
